In today’s ACT Brief, we explore how Eli Lilly’s orforglipron could become the first oral GLP-1 therapy reviewed under FDA’s new national priority program, and examine emerging regulatory and ethical ...

Now, with the MATTERHORN data, we’ve seen that when we start with Imfinzi—or an IO—in a perioperative setting, which ...

Explore how AstraZeneca’s immuno-oncology strategy focuses on improving survival in hard-to-treat cancers and moving checkpoint inhibitors into curative-intent settings.

Welcome to this special recap of this year’s SCRS Global Site Solutions Summit, where industry leaders gathered to share insights on strengthening collaboration between sponsors, CROs, and sites. The ...

Because the data [are] contextualized, we know who the physicians are [that are] working with the patients we aspire to treat ...

In today’s ACT Brief, we spotlight the industry’s push to reduce site technology burden, AstraZeneca’s broad survival gains ...

Gain insight into how the MATTERHORN trial’s results across PD-L1 subgroups could expand access to immunotherapy and reshape ...

ACT: The MATTERHORN trial showed a 22% reduction in the risk of death with the Imfinzi regimen. How significant is this ...

See Agentic AI in action as it eases site payments manual processes such as Clinical Trial Agreements (CTAs) ingestion and ...

Learn how increasing system complexity and patient-facing technologies are creating new burdens for clinical trial sites—and what vendors and sponsors can do to streamline operations and improve ...

In today’s ACT Brief, we explore how AstraZeneca is redefining gastric cancer care through the MATTERHORN trial, Phesi’s Gen Li shares how AI and patient data are advancing global trial equity, and ...